The European Commission announced yesterday that it has launched a formal investigation into Aspen Pharma’s pricing of five cancer drugs. The Commission will investigate whether Aspen Pharma abused a dominant position, in breach of Article 102 of the Treaty on the Functioning of the European Union (TFEU), by imposing significant price increases for the drugs in question. The Commission will also investigate allegations that Aspen Pharma threatened to (or did) withdraw the drugs in some EU Member States.
Cases alleging unfair – or excessive – pricing are notoriously complex, and the Commission’s investigation of Aspen Pharma may cause it to have to play the role of an unofficial price regulator (in addition to the Member State authorities that have primary responsibility for drug procurement in the EU).
Sidley Austin LLP provides this information as a service to clients and other friends for educational purposes only. It should not be construed or relied on as legal advice or to create a lawyer-client relationship.
Attorney Advertising - For purposes of compliance with New York State Bar rules, our headquarters are Sidley Austin LLP, 787 Seventh Avenue, New York, NY 10019, 212.839.5300; One South Dearborn, Chicago, IL 60603, 312.853.7000; and 1501 K Street, N.W., Washington, D.C. 20005, 202.736.8000.